Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Apnimed has found its new medical director in Luigi Taranto Montemurro, Apnimed’s co-founder and prior instructor of medicine at Brigham and Women’s Hospital and Harvard Medical School.
Nils Lonberg has been added to the scientific advisory board of Bolt Therapeutics. Dr. Lonberg is an executive-in-residence at early-stage venture capital firm Canaan Partners.
Ignacio Garcia-Ribas, who most recently served as the senior medical director at Takeda, has been named chief medical officer of Cantargia.
Endo’s chief financial officer Blaise Coleman has replaced Paul Campanelli, the former CEO of the company.
Epirium Bio has tapped Cristina Ghenoiu as the firm’s new senior vice president of research and development operations and new product planning. Prior to this appointment, Ghenoiu was a senior investment professional at Longitude Capital.
Pol Boudes has been appointed to the role of chief medical officer at Galectin Therapeutics. Boudes was most recently the chief medical officer at CymaBay Therapeutics.
Michael Quigley has joined Gilead Sciences as its new head of research biology. Quigley was most recently the vice president and head of the Big Pharma’s Tumor Microenvironment Modulation Thematic Research Center.
H3 Biomedicine has appointed Antonio Gualberto to the role of chief medical officer. Prior to this appointment, Gualberto served as co-founder and chief medical officer at Kura Oncology.
Loretta Itri is now chief medical officer for Immunomedics, joining the company from The Medicines Company, where she served as executive vice president of global health sciences and regulatory affairs.
Merck’s vice president of animal health IT, Dave Williams, has assumed the role of interim chief information and digital officer, following Jim Scholefield’s departure from the company.
Tim Hohm has been named director of commercial strategy and business development for Optibrium. Previously, Hohm was senior competitive intelligence manager at Novo Nordisk.
Panorama Medicine has named Jae Lee as its newest executive vice president of research and preclinical development, joining the organization after serving as vice president of preclinical development at Kintai Therapeutics.
Turning Point Therapeutics
Turning Point Therapeutics has appointed Siegfried Reich to the position of executive vice president and chief scientific officer. Most recently, Reich served as senior vice president of research and co-founder of
Matthew Roe has been named chief medical officer of Verana Health, joining the company after most recently serving as a co-principal investigator for the ADAPTABLE trial, a real-world data study.
Worldwide Clinical Trials
Mike Mencer has been hired as Worldwide Clinical Trials’ executive vice president and general manager of the contract research organization’s early-phase services. Previously, Mencer was executive director of business development operations at Acurian.
Michael Yaremchuk, a clinical professor of surgery at the Harvard Medical School and chief of craniofacial surgery at the Massachusetts General Hospital, has joined XenoTherapeutics as the company’s first chief medical officer.